{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:57:55Z","timestamp":1793750275099,"version":"4.6.1"},"reference-count":43,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2020,1,1]]},"DOI":"10.1001\/jamadermatol.2019.3336","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T11:31:27Z","timestamp":1573039887000},"page":"44","source":"Crossref","is-referenced-by-count":496,"title":["Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis"],"prefix":"10.1001","volume":"156","author":[{"given":"Eric L.","family":"Simpson","sequence":"first","affiliation":[{"name":"Department of Dermatology, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois"},{"name":"Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine C.","family":"Siegfried","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, Saint Louis University, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Boguniewicz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, Denver"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Sher","sequence":"additional","affiliation":[{"name":"Peninsula Research Associates, Rolling Hills Estates, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda J.","family":"Gooderham","sequence":"additional","affiliation":[{"name":"Skin Centre for Dermatology, Peterborough, Ontario, Canada"},{"name":"Department of Medicine, Queen's University, Kingston, Ontario, Canada"},{"name":"Probity Medical Research, Waterloo, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Beck","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Rochester Medical Center, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Laboratory for Investigative Dermatology, Rockefeller University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pariser","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Eastern Virginia Medical School, Norfolk"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[{"name":"Oregon Medical Research Center, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Weisman","sequence":"additional","affiliation":[{"name":"Advanced Medical Research, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lockshin","sequence":"additional","affiliation":[{"name":"US Dermatology Partners, Rockville, Maryland"},{"name":"Georgetown University, Washington, District of Columbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hultsch","sequence":"additional","affiliation":[{"name":"Sanofi Genzyme, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Kamal","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Davis","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolanle","family":"Akinlade","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heribert","family":"Staudinger","sequence":"additional","affiliation":[{"name":"Sanofi, Bridgewater, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer D.","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M. H.","family":"Graham","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Pirozzi","sequence":"additional","affiliation":[{"name":"Sanofi, Bridgewater, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Gadkari","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Eckert","sequence":"additional","affiliation":[{"name":"Sanofi, Chilly-Mazarin, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Stahl","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George D.","family":"Yancopoulos","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Ruddy","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Bansal","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"doi190057r1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jid.2016.08.022","article-title":"Increasing comorbidities suggest that atopic dermatitis is a systemic disorder.","volume":"137","author":"Brunner","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"8","key":"doi190057r2","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s12325-017-0582-z","article-title":"Burden of atopic dermatitis in the United States: analysis of healthcare claims data in the commercial, Medicare, and Medi-Cal databases.","volume":"34","author":"Shrestha","year":"2017","journal-title":"Adv Ther"},{"issue":"6","key":"doi190057r3","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s40257-018-0383-4","article-title":"Major comorbidities of atopic dermatitis: beyond allergic disorders.","volume":"19","author":"Paller","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"doi190057r4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/jid.2010.251","article-title":"Eczema prevalence in the United States: data from the 2003 National Survey of Children\u2019s Health.","volume":"131","author":"Shaw","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"6","key":"doi190057r5","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jaci.2009.10.009","article-title":"Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three.","volume":"124","author":"Odhiambo","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"doi190057r7","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/pai.12095","article-title":"Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization.","volume":"24","author":"Silverberg","year":"2013","journal-title":"Pediatr Allergy Immunol"},{"issue":"6","key":"doi190057r8","doi-asserted-by":"publisher","first-page":"711","DOI":"10.2340\/00015555-2633","article-title":"Quality of life of parents of children with atopic dermatitis.","volume":"97","author":"Marciniak","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"doi190057r9","doi-asserted-by":"crossref","DOI":"10.4081\/dr.2012.e1","article-title":"Atopic dermatitis in adolescence.","volume":"4","author":"Ricci","year":"2011","journal-title":"Dermatol Reports"},{"issue":"3","key":"doi190057r10","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.jaci.2011.05.003","article-title":"Depression, anxiety, and dermatologic quality of life in adolescents with atopic dermatitis.","volume":"128","author":"Slattery","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"doi190057r11","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1038\/jid.2014.70","article-title":"Suicidal ideation, mental health problems, and social function in adolescents with eczema: a population-based study.","volume":"134","author":"Halvorsen","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"2","key":"doi190057r12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents.","volume":"71","author":"Sidbury","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi190057r13","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/bjd.15928","article-title":"Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement.","volume":"178","author":"Drucker","year":"2018","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi190057r14","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jaad.2016.09.021","article-title":"Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey.","volume":"76","author":"Totri","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"14","key":"doi190057r15","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes.","volume":"111","author":"Macdonald","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"doi190057r16","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice.","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"doi190057r17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases.","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"doi190057r18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"24","key":"doi190057r19","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"SOLO 1 and SOLO 2 Investigators. Two phase 3 trials of dupilumab vs. placebo in atopic dermatitis.","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"issue":"10086","key":"doi190057r20","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"doi190057r21","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1111\/bjd.2018.178.issue-5","article-title":"Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9).","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"issue":"10039","key":"doi190057r24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u00df2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"issue":"26","key":"doi190057r25","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma.","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"doi190057r26","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma.","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"doi190057r27","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial.","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"doi190057r28","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"doi190057r29","article-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis","author":"Hirano","journal-title":"Gastroenterology"},{"issue":"20","key":"doi190057r34","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"doi190057r35","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","article-title":"Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.","volume":"70","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"10013","key":"doi190057r36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.","volume":"387","author":"Tha\u00e7i","year":"2016","journal-title":"Lancet"},{"key":"doi190057r37","article-title":"Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension","author":"Cork","journal-title":"Br J Dermatol"},{"issue":"4","key":"doi190057r39","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00403-011-1198-9","article-title":"Association of serum interleukin-18 and other biomarkers with disease severity in adults with atopic dermatitis.","volume":"304","author":"Kou","year":"2012","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"doi190057r40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.iac.2016.08.008","article-title":"Current and future biomarkers in atopic dermatitis.","volume":"37","author":"Thijs","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"issue":"3","key":"doi190057r41","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.jid.2016.09.037","article-title":"An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease.","volume":"137","author":"Ungar","year":"2017","journal-title":"J Invest Dermatol"},{"key":"doi190057r42","doi-asserted-by":"publisher","first-page":"8707","DOI":"10.1038\/s41598-017-09207-z","article-title":"The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins.","volume":"7","author":"Brunner","year":"2017","journal-title":"Sci Rep"},{"key":"doi190057r43","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2019.08.050","article-title":"Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma","author":"Corren","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"doi190057r6","unstructured":"Data Resource Center for Child & Adolescent Health. National Survey of Children\u2019s Health. http:\/\/www.childhealthdata.org. Published 2007. Accessed April 18, 2019."},{"key":"doi190057r22","unstructured":"Dupixent (dupilumab) injection [package insert]. United States Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761055s014lbl.pdf. Published June 2019. Accessed August 19, 2019."},{"key":"doi190057r23","unstructured":"Dupixent (dupilumab) Summary of product characteristics. European Medicines Agency. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004390\/WC500236507.pdf. Published June 5, 2019. Accessed August 19, 2019."},{"key":"doi190057r30","unstructured":"ClinicalTrials.gov. Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE). NCT03633617. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03633617. Accessed October 4, 2019."},{"key":"doi190057r31","unstructured":"ClinicalTrials.gov. Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients =6 Months to <6 Years With Severe Atopic Dermatitis (Liberty AD PRESCHOOL). NCT03346434. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03346434. Accessed October 4, 2019."},{"key":"doi190057r32","unstructured":"ClinicalTrials.gov. Evaluation of Dupilumab in Children With Uncontrolled Asthma (VOYAGE). NCT02948959. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02948959. Accessed July 5, 2019."},{"key":"doi190057r33","unstructured":"ClinicalTrials.gov. Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy). NCT03682770. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03682770. Accessed July 5, 2019."},{"key":"doi190057r38","unstructured":"MedDRA. Medical Dictionary for Regulatory Activities. https:\/\/www.meddra.org\/how-to-use\/support-documentation\/english. Accessed October 4, 2019."}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2753673\/jamadermatology_simpson_2019_oi_190057.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T11:02:16Z","timestamp":1578481336000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2753673"}},"subtitle":["A Phase 3 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,1,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2019.3336","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1,1]]}}}